p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors

Cell Cycle

Volumn 11, Issue 3, 2012, Pages 543-553

  Sanhaji, Mourad ^a   Kreis, Nina Naomi ^a   Zimmer, Brigitte ^a   Berg, Thorsten ^b,c   Louwen, Frank ^a   Yuan, Juping ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

BI 2536; BI 6727; p53; Polo like kinase 1; Poloxin

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; PROTEIN P53; SMALL INTERFERING RNA; VOLASERTIB; BENZOIC ACID DERIVATIVE; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; POLOXIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; QUINONE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA REPLICATION; GENOMIC INSTABILITY; HELA CELL; HUMAN; HUMAN CELL; LUNG CANCER; UTERINE CERVIX CARCINOMA; CELL PROLIFERATION; CELL STRAIN HCT116; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; RNA INTERFERENCE; TUMOR CELL LINE;

BENZOATES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; GENOMIC INSTABILITY; HCT116 CELLS; HELA CELLS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; QUINONES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857211813     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.3.19076     Document Type: Article

References (48)

1. Takaki T, Trenz K, Costanzo V, Petronczki M. Pololike kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response and development. Curr Opin Cell Biol 2008; 20:650-60; PMID:19000759; http:// dx.doi.org/10.1016/j.ceb.2008.10. 005.
2. Petronczki M, Lénárt P, Peters JM. Polo on the Risefrom Mitotic Entry to Cytokinesis with Plk1. Dev Cell 2008; 14:646-59; PMID:18477449; http://dx.doi. org/10.1016/j.devcel.2008.04.014.
3. de Cárcer G, Manning G, Malumbres M. From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 2011; 10:2255-62; PMID:21654194; http:// dx.doi.org/10.4161/cc.10.14.16494.
4. Lee HJ, Hwang HI, Jang YJ. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway. Cell Cycle 2010; 9:2389-98; PMID:20581453; http://dx.doi. org/10.4161/cc.9.12.11904.
5. Tsvetkov L, Stern DF. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage. Cell Cycle 2005; 4:166-71; PMID:15611664; http:// dx.doi.org/10.4161/cc.4.1.1348.
6. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643-60; PMID:20671765; http:// dx.doi.org/10.1038/nrd3184.
7. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10:265- 75; PMID:19305416; http://dx.doi.org/10.1038/ nrm2653.
8. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24:267-76; PMID:15640842; http://dx.doi.org/10.1038/ sj.onc.1208273.
9. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30; PMID:16557283; http://dx.doi.org/10.1038/ nrc1841.
10. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137:835- 48; PMID:19490893; http://dx.doi.org/10.1016/j. cell.2009.05.006.
11. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10:825-41; PMID:21102634; http://dx.doi.org/10.1038/nrc2964.
12. Taylor S, Peters JM. Polo and Aurora kinases: lessons derived from chemical biology. Curr Opin Cell Biol 2008; 20:77-84; PMID:18249108; http://dx.doi. org/10.1016/j.ceb.2007.11.008.
13. Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle 2010; 9:761-73; PMID:20139717; http:// dx.doi.org/10.4161/cc.9.4.10644.
14. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316- 22; PMID:17291758; http://dx.doi.org/10.1016/j. cub.2006.12.037.
15. Lénárt P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007; 17:304- 15; PMID:17291761; http://dx.doi.org/10.1016/j. cub.2006.12.046.
16. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009; 15:3094-102; PMID:19383823; http://dx.doi. org/10.1158/1078-0432.CCR-08-2445.
17. Santamaria A, Neef R, Eberspächer U, Eis K, Husemann M, Mumberg D, et al. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 2007; 18:4024-36; PMID:17671160; http:// dx.doi.org/10.1091/mbc.E07-05-0517.
18. Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007; 6:450-9; PMID:17267659; http://dx.doi.org/10.1158/1535-7163.MCT-06-0543.
19. Elia AE, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K, et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polobox domain. Cell 2003; 115:83-95; PMID:14532005; http://dx.doi.org/ 10.1016/S0092-8674(03)00725-6.
20. Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T. Inhibition of polo-like kinase 1 by blocking polobox domain-dependent protein-protein interactions. Chem Biol 2008; 15:459-66; PMID:18482698; http:// dx.doi.org/10.1016/j.chembiol.2008.03.013.
21. Watanabe N, Sekine T, Takagi M, Iwasaki J, Imamoto N, Kawasaki H, et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domaindependent recognition. J Biol Chem 2009; 284:2344- 53; PMID:19033445; http://dx.doi.org/10.1074/jbc. M805308200.
22. Yuan J, Sanhaji M, Krämer A, Reindl W, Hofmann M, Kreis NN, et al. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol 2011; 179:2091- 9; PMID:21839059; http://dx.doi.org/10.1016/j. ajpath.2011.06.031.
23. Liu F, Park JE, Qian WJ, Lim D, Gräber M, Berg T, et al. Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol 2011; 7:595- 601; PMID:21765407; http://dx.doi.org/10.1038/ nchembio.614.
24. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009; 14:559-70; PMID:19474163; http://dx.doi.org/10.1634/theoncologist.2009-0010.
25. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010; 46:2206- 15; PMID:20471824; http://dx.doi.org/10.1016/j. ejca.2010.03.039.
26. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008; 26:5511-7; PMID:18955456; http://dx.doi.org/10.1200/JCO.2008.16.1547.
27. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-94; PMID:12732729; http:// dx.doi.org/10.1073/pnas.1031523100.
28. Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94:1863- 77; PMID:12488480; http://dx.doi.org/10.1093/ jnci/94.24.1863.
29. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26:2093-108; PMID:16507989; http://dx.doi. org/10.1128/MCB.26.6.2093-108.2006.
30. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65:2698-704; PMID:15805268; http://dx.doi. org/10.1158/0008-5472.CAN-04-2131.
31. Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther 2010; 9:2079-89; PMID:20571075; http:// dx.doi.org/10.1158/1535-7163.MCT-10-0095.
32. Lu B, Mahmud H, Maass AH, Yu B, van Gilst WH, de Boer RA, et al. The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. PLoS One 2010; 5:12963; PMID:20886032; http://dx.doi.org/10.1371/journal. pone.0012963.
33. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505; PMID:8221889; http:// dx.doi.org/10.1016/0092- 8674(93)90384-3.
34. Kreis NN, Sanhaji M, Krämer A, Sommer K, Rödel F, Strebhardt K, et al. Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells. Oncogene 2010; 29:5591-603; PMID:20661218; http://dx.doi. org/10.1038/onc.2010.290.
35. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7:107-17; PMID:17251917; http://dx.doi.org/10.1038/nrc2049.
36. McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, et al. p53-dependent repression of pololike kinase-1 (PLK1). Cell Cycle 2010; 9:4200-12; PMID:20962589; http://dx.doi.org/10.4161/ cc.9.20.13532.
37. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004; 279:25549-61; PMID:15024021; http://dx.doi.org/10.1074/jbc.M314182200.
38. Yang X, Li H, Zhou Z, Wang WH, Deng A, Andrisani O, et al. Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem 2009; 284:18588- 92; PMID:19473992; http://dx.doi.org/10.1074/jbc. C109.001560.
39. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, et al. A part of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 2009; 106:3964- 9; PMID:19225112; http://dx.doi.org/10.1073/ pnas.0813333106.
40. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009; 9:724-37; PMID:19776742; http://dx.doi.org/10.1038/nrc2730.
41. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862-73; PMID:19935675; http://dx.doi.org/10.1038/nrc2763.
42. 2 after ionizing radiation. Cell Cycle 2011; 10:819-29; PMID:21325885; http://dx.doi. org/10.4161/cc.10.5.14968.
43. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222-33; PMID:21447859.
44. Ohnishi T. The role of the p53 molecule in cancer therapies with radiation and/or hyperthermia. J Cancer Res Ther 2005; 1:147-50; PMID:17998646; http:// dx.doi.org/10.4103/0973-1482.19594.
45. Steelman LS, Martelli AM, Nicoletti F, McCubrey JA. Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. Oncotarget 2011; 2:109-12; PMID:21487160.
46. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, et al. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget 2010; 1:639-50; PMID:21317459.
47. Kreis NN, Sommer K, Sanhaji M, Krämer A, Matthess Y, Kaufmann M, et al. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle 2009; 8:460- 72; PMID:19177004; http://dx.doi.org/10.4161/ cc.8.3.7651.
48. Sanhaji M, Friel CT, Kreis NN, Krämer A, Martin C, Howard J, et al. Functional and spatial regulation of mitotic centromere-associated kinesin by cyclindependent kinase 1. Mol Cell Biol 2010; 30:2594- 607; PMID:20368358; http://dx.doi.org/10.1128/ MCB.00098-10.